| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Cardinal Health, Inc.$227.47
-0.25 (-0.11%)
D 26Pipeline Score Tools & Services · Commercial
Market Cap
50.72 B
EPS
6.98
P/E Ratio
31.02 $
Value Trade
237.80 M
SEC Financials
Q4 2025Dilution Risk
Revenue
65.63 B
Total Assets
58.08 B
Total Liabilities
58.08 B
Equity
-2.88 B
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
2.78 B
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
Feb 5, 2026
Overview
Volume
437.07 K
52 Week Range
129.52 - 233.60
% held by Insiders
0.25 %
% held by Institutions
89.21 %
Enterprise Value
57.15 B
Total Shares
235.27 M
Short %
3.36 %
Float Shares
235.03 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D26
Pipeline Score $298M
Pipeline ValueValuation Signal
2
Drugs Scored0.0x
rNPV / MCap Top 28%
Large Pharma (rank 653 of 905)
Percentile RankCardinal Health, Inc. faces pipeline headwinds (26/100), with $298M risk-adjusted pipeline value, led by Tc99m tilmanocept in Rhabdomyosarcoma (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tc99m tilmanocept Small molecule | Rhabdomyosarcoma | Phase 2 | NCT02509598 | 10% | $201M | COMPLETED | 24 | - | - | Mar 6, 2019 | - | Jun 28, 2024 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CAH
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Cardinal Health, Inc. (CAH) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
CAH
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CAH
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CAH
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CAH Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
CAH Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-06-26 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-06-26 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-06-26 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-CAH
May 5, 2026Cardinal Health Board of Directors Approves Quarterly Dividend
Cardinal Health's Board of Directors has approved a quarterly dividend increase to $0.5158 per share, which will be paid on July 15, 2026. Shareholders of record as of July 1, 2026, will receive this dividend, highlighting the company's ongoing commitment to returning value to its investors. This decision underscores Cardinal Health's financial health and operational success.
Read more →-CAH
Apr 14, 2026Cardinal Health report highlights growing momentum to expand advanced therapies into community care settings
Cardinal Health's 2026 Advanced Therapies Report reveals a shift towards administering advanced therapies in community settings. The report highlights strong provider support for these initiatives, emphasizing the importance of partnerships between health systems and community practices. It also notes the operational complexities and planning required to successfully implement these programs, which aim to enhance patient access and experience.
Read more →Competitive Position
How CAH ranks across every disease it competes inCompetitive Position is a premium feature
See how CAH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial